Zealand’s Dasiglucagon Down But Not Out In CHI?
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
You may also be interested in...
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).